Bob Lederer RBDR

Data careers: good or bad? Low phone responses not major polling error source. (RBDR 02.16.2016)

Today on RBDR:

1) A top executive recruiter questions whether it is a good idea for parents and their children to alter their career course and target analytics and data science.

2) The Huffington Post claims that plummeting telephone response cooperation is not a major cause of polling errors.

RBDR is sponsored by L&E Research, where recruiting is their passion. Quality respondents plus quality information. It’s that simple.

Visit their website, and check out their post about how to find and put together all the elements that can gain a clearer picture of “the whole truth” in any project for researchers. Read it here.

There is no need to search for today’s RBDR video. Subscribe (it’s FREE) to receive a personal email as soon as the new RBDR is uploaded. Click here.

Bob Lederer RFL Communications, Inc.

Patient Identity theft, Fitbit, Apple Watch disgust, Hospital mistakes public (PRVR 9/15 – 19/2014)

Pharma Research VIDEO Report is sponsored by the Toluna Healthcare Practice, offering highly engaged physicians, health professionals and ailment sufferers for global research using cutting-edge methodologies, sophisticated, yet easy-to-use analytic tools and specialized products including Pharmacy Intercept, dedicated communities, patient record studies and more.

Toluna Healthcare Practice is recommending everyone read this Kaiser Family Foundation release for its emphasis on the growing importance of patients in industry research:

http://kff.org/health-costs/report/2014-employer-health-benefits-survey/

This week on PRVR: 1) The Boston Globe warns about the seriousness and dangers from stolen patient records. 2) Dick Vanderveer’s September 11 blog mentions FitBit’s legal right to sell data the device collects. 3) Federal regulators have decided to reverse course and begin making public records of eight hospital patient mistakes. 4) The Apple Watch introduction paid scant attention to healthcare. 5) India’s poor patent laws with Rx drugs are severely limiting the number of new drugs being made available there. 6) Big Data has brought at least four important benefits for healthcare.

Bob Lederer RFL Communications, Inc.

Comparing Observational MR; Proposed Part D changes; FDA generic Rx initiative; HIMSS reports on HC mobile implementation vs. usage; MDLinx verifying European MDs; Novartis expands clinical data transparency; SAP testing “Medical Insights” cancer patient assistance (PMRVR–3/4/14)

In this Pharma Market Research VIDEO Report:  1) GRACE, an 11-item checklist of data and methods, allows testing of baseline quality criteria for observational research.  2) The CMS is proposing changes to Medicare Part D. The big picture change calls for stopping automatic Medicare coverage of two drug classes; the underlying consideration in the plan could lead to federal government price negotiations with pharmacos (expressly forbidden in legislation that established Part D).  3) The FDA launches a $20 million initiative to test generic drug production, which represents 80% of Rx drugs. India, wiht its $15 billion in annual generic drug production, is a primary focus but China is also in the crosshairs. 4) HIMSS mobile research study investigates its implementation and use by healthcare providers.  5) GfK reports an upsurge in 2013 in purchase of mobile-connected medical devices in top European countries.  6) MDLinx is launching its physician verification service in Europe.  7) The Kaiser Family Foundation reports users of the ACA website were more price-oriented than physician-focused.  8) Novartis says it has extended its pharmaco leadership in clinical trial data transparency.  9) SAP is testing “Medical Insights,” a capability that aids cancer patients by pulling relevant data from many cancer data sources, runs advanced analytics and delivers customized results in real time.